Treatment of Multiple Myeloma: Best Practices from Yale Cancer Center and Satellites

home / satellite-sessions / treatment-of-multiple-myeloma-best-practices-from-yale-cancer-center-and-satellites

A Satellite Sessions program at the Yale Cancer Center discusses treatment paradigms and unmet needs in multiple myeloma as well as transplantation, bispecific T-cell engaging therapies, and the importance of collaborative decision-making in clinical practice.

EP. 1: The ‘Golden Age’ of Daratumumab: Highlights From an Expert Panel on Multiple Myeloma

June 8th 2023

A Satellite Sessions program at the Yale Cancer Center discusses treatment paradigms and unmet needs in multiple myeloma as well as transplantation, bispecific T-cell engaging therapies, and the importance of collaborative decision-making in clinical practice.

EP. 2: Triplet and Quadruplet Induction Regimen Options for Patients With Transplant-Eligible NDMM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

June 12th 2023

Natalia Neparidze, MD, reviews the available induction treatment options for patients with newly diagnosed multiple myeloma (NDMM).

EP. 3: Data Updates From GRIFFIN and MASTER in Transplant-Eligible NDMM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

June 12th 2023

David Witt, MD, details the design and outcomes of the GRIFFIN study in newly diagnosed multiple myeloma.

EP. 4: Exploring the GMMG-CONCEPT Study in Patients With Transplant-Eligible NDMM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

June 19th 2023

Noffar Bar, MD, explains the GMMG-CONCEPT trial in patients with transplant-eligible NDMM.

EP. 5: Assessing and Treating Patients with High-Risk NDMM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

June 19th 2023

Elan Gorshein, DO, JD, MPH, describes potential approaches to managing high-risk patients with transplant-eligible NDMM.

EP. 6: Treatment Approaches in Patients With Transplant-Ineligible NDMM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

June 26th 2023

Noffar Bar, MD, discusses the MAIA study investigating a daratumumab combination therapy in patients with transplant-ineligible multiple myeloma.

EP. 7: Subset Analysis of the MAIA Study in the Frail Multiple Myeloma Population

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

June 26th 2023

Experts comment on the subset analysis of the MAIA study in the frail NDMM patient population.

EP. 8: Available Treatment Options for Patients With R/R MM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 3rd 2023

Elan Gorshein, DO, JD, MPH, explains his choice of frontline therapy for patients with relapsed/refractory multiple myeloma.

EP. 9: Updated Results of the MonumenTAL-1 Study in R/R MM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 3rd 2023

Noffar Bar, MD, details data on talquetamab in R/R MM treatment from the MonumenTAL-1 study, and Syed S. Ali, MD, speaks to his experience with teclistamab in clinical practice.

EP. 10: Application of Bispecific Therapy in Clinical Practice

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 10th 2023

Syed S. Ali, MD, and Noffar Bar, MD, share their practical experience with bispecific antibodies in the treatment of patients with multiple myeloma.

EP. 11: Discussing Bispecific Antibody Treatment With Patients With Multiple Myeloma

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 10th 2023

Catherine Wei, MD, and David Witt, MD, explain some of the reasons they would recommend treatment with bispecific antibodies to their patients with multiple myeloma.

EP. 12: Comparing Bispecifics and CAR T-Cell Therapy for Patients With MM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 17th 2023

Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.

EP. 13: Unmet Needs in the Treatment of Multiple Myeloma

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 17th 2023

The panel highlights remaining unmet needs in the management of multiple myeloma and speculates on the future of treatment.

EP. 14: Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and Satellites

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 24th 2023

A Q&A session with the expert panel.